Discover how Paragraph IV certification enables generic drugs to challenge brand-name patents under the Hatch-Waxman Act. Learn about the 30-month stay, 180-day exclusivity rewards, and the legal strategies shaping pharmaceutical competition.
Landmark court decisions in generic patent law shape drug prices and access. Key rulings like Amgen v. Sanofi and Allergan v. Teva define how generics challenge patents, use the Orange Book, and navigate the Hatch-Waxman Act-impacting millions of patients.